Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment

Movement Disorders

Volumn 25, Issue 11, 2010, Pages 1568-1576

  Belujon, Pauline ^a   Lodge, Daniel J ^a,b   Grace, Anthony A ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Basal ganglia; Dopamine; Motor cortex; Parkinson's disease; Synaptic plasticity

Indexed keywords

DOPAMINE; LEVODOPA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; BRAIN NERVE CELL; CONTROLLED STUDY; CORPUS STRIATUM; DYSKINESIA; IN VIVO STUDY; INFORMATION PROCESSING; LONG TERM DEPRESSION; LONG TERM POTENTIATION; NERVE CELL PLASTICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

ACTION POTENTIALS; ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; CHOLERA TOXIN; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DYSKINESIA, DRUG-INDUCED; FLUORESCENT DYES; LEVODOPA; LONG-TERM POTENTIATION; NEURONAL PLASTICITY; NEURONS; OXIDOPAMINE; PARKINSON DISEASE; RATS; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 77955828413     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23245     Document Type: Article

References (38)

1. Ehringer H, Hornykiewicz O. [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system.] Klin Wochenschr 1960;38:1236-1239.
2. Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1977;1:345-349.
3. Bedard PJ, Blanchet PJ, Levesque D, et al. Pathophysiology of L-dopa-induced dyskinesias. Mov Disord 1999;14(suppl 1):4-8.
4. Calabresi P, Giacomini P, Centonze D, Bernardi G. Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? Ann Neurol 2000;47(4 suppl 1):S60-S68; discussion S68-S69.
5. Chase TN, Oh JD. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci 2000;23(10 suppl):S86-S91.
6. Picconi B, Centonze D, Hakansson K, et al. Loss of bidirectional striatal synaptic plasticity in L-dopa-induced dyskinesia. Nat Neurosci 2003;6:501-506.
7. Calabresi P, Pisani A, Mercuri NB, Bernardi G. Long-term potentiation in the striatum is unmasked by removing the voltage- dependent magnesium block of NMDA receptor channels. Eur J Neurosci 1992;4:929-935.
8. Mahon S, Deniau JM, Charpier S. Corticostriatal plasticity: life after the depression. Trends Neurosci 2004;27:460-467.
9. Pisani A, Centonze D, Bernardi G, Calabresi P. Striatal synaptic plasticity: implications for motor learning and Parkinson's disease.. Mov Disord 2005;20:395-402. (Pubitemid 40779013)
10. Le Moine C, Bloch B. D1 and D2 dopamine receptor gene expression in the rat striatum: sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum. J Comp Neurol 1995;355:418-426.
11. Gerfen CR. Molecular effects of dopamine on striatal-projection pathways. Trends Neurosci 2000;23(10 suppl):S64-S70.
12. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, et al. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 2000;23(10 suppl):S8-S19.
13. Onn SP, West AR, Grace AA. Dopamine-mediated regulation of striatal neuronal and network interactions. Trends Neurosci 2000; 23(10 suppl):S48-S56.
14. Onn SP, Berger TW, Grace AA. Identification and characterization of striatal cell subtypes using in vivo intracellular recording in rats: I. Basic physiology and response to corticostriatal fiber stimulation. Synapse (New York, NY) 1994;16: 161-180.
15. Belujon P, Bezard E, Taupignon A, Bioulac B, Benazzouz A. Noradrenergic modulation of subthalamic nucleus activity: behavioral and electrophysiological evidence in intact and 6- hydroxydopamine-lesioned rats. J Neurosci 2007;27:9595-9606.
16. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 2002;15:120-132.
17. Cenci MA, Lee CS, Bjorklund A. L-dopa-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin-and glutamic acid decarboxylase mRNA. Eur J Neurosci 1998; 10:2694-2706.
18. Napolitano A, Zurcher G, Da Prada M. Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats. European journal of pharmacology 1995;273:215-221.
19. Rodriguez M, Morales I, Gonzalez-Mora JL, et al. Different levodopa actions on the extracellular dopamine pools in the rat striatum. Synapse (New York, NY) 2007;61:61-71.
20. Onn SP, Berger TW, Grace AA. Identification and characterization of striatal cell subtypes using in vivo intracellular recording in rats: II. Membrane factors underlying paired-pulse response profiles. Synapse (New York, NY) 1994;16:195-210.
21. Paxinos G, Watson C. The rat brain in stereotatic coordinates. San Diego: Academic Press; 1996.
22. Jedema HP, Grace AA. Chronic exposure to cold stress alters electrophysiological properties of locus coeruleus neurons recorded in vitro. Neuropsychopharmacology 2003;28:63-72.
23. Onn SP, Berger TW, Grace AA. Identification and characterization of striatal cell subtypes using in vivo intracellular recording and dye-labeling in rats: III. Morphological correlates and compartmental localization. Synapse (New York, NY) 1994;16:231-254.
24. Lovinger DM, Tyler EC, Merritt A. Short- and long-term synaptic depression in rat neostriatum. J Neurophysiol 1993;70:1937-1949.
25. Ronesi J, Lovinger DM. Induction of striatal long-term synaptic depression by moderate frequency activation of cortical afferents in rat. J Physiol 2005;562(Pt 1):245-256.
26. Centonze D, Calabresi P, Giacomini P, Bernardi G. Neurophysiology of Parkinson's disease: from basic research to clinical correlates. Clin Neurophysiol 1999;110:2006-2013.
27. Centonze D, Grande C, Saulle E, et al. Distinct roles of D1 and D5 dopamine receptors in motor activity and striatal synaptic plasticity. J Neurosci 2003;23:8506-8512.
28. Dalbem A, Silveira CV, Pedroso MF, et al. Altered distribution of striatal activity-dependent synaptic plasticity in the 3-nitropropionic acid model of Huntington's disease. Brain Res 2005;1047: 148-158.
29. Yasui T, Fujisawa S, Tsukamoto M, Matsuki N, Ikegaya Y. Dynamic synapses as archives of synaptic history: state-dependent redistribution of synaptic efficacy in the rat hippocampal CA1. J Physiol 2005;566(Pt 1):143-160.
30. Fitzpatrick JS, Akopian G, Walsh JP. Short-Term Plasticity at Inhibitory Synapses in Rat Striatum and Its Effects on Striatal Output. J Neurophysiol 2001;85:2088-2099.
31. Mallet N, Ballion B, Le Moine C, Gonon F. Cortical inputs and GABA interneurons imbalance projection neurons in the striatum of parkinsonian rats. J Neurosci 2006;26:3875-3884.
32. Reynolds JN, Wickens JR. Substantia nigra dopamine regulates synaptic plasticity and membrane potential fluctuations in the rat neostriatum, in vivo. Neuroscience 2000;99:199-203.
33. Calabresi P, Saiardi A, Pisani A, et al. Abnormal synaptic plasticity in the striatum of mice lacking dopamine D2 receptors. J Neurosci 1997;17:4536-4544. (Pubitemid 27246911)
34. Wang Z, Kai L, Day M, et al. Dopaminergic control of corticostriatal long-term synaptic depression in medium spiny neurons is mediated by cholinergic interneurons. Neuron 2006;50:443-452.
35. Calabresi P, Maj R, Pisani A, Mercuri NB, Bernardi G. Long-term synaptic depression in the striatum: physiological and pharmacological characterization. J Neurosci 1992;12:4224-4233.
36. Charpier S, Deniau JM. In vivo activity-dependent plasticity at cortico-striatal connections: evidence for physiological long-term potentiation. Proc Natl Acad Sci U S A 1997;94:7036-7040.
37. Olanow CW, Gauger LL, Cedarbaum JM. Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease. Ann Neurol 1991;29:556-559.
38. Blanchet PJ, Calon F, Morissette M, et al. Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms. Parkinsonism Relat Disord 2004;10:297-304.